| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNLS |
| Uniprot No | Q5VYX0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-342aa |
| 氨基酸序列 | MAQVLIVGAGMTGSLCAALLRRQTSGPLYLAVWDKADDSGGRMTTACSPH NPQCTADLGAQYITCTPHYAKKHQRFYDELLAYGVLRPLSSPIEGMVMKE GDCNFVAPQGISSIIKHYLKESGAEVYFRHRVTQINLRDDKWEVSKQTGS PEQFDLIVLTMPVPEILQLQGDITTLISECQRQQLEAVSYSSRYALGLFY EAGTKIDVPWAGQYITSNPCIRFVSIDNKKRNIESSEIGPSLVIHTTVPF GVTYLEHSIEDVQELVFQQLENILPGLPQPIATKCQKWRHSQVTNAAANC PGQMTLHHKPFLACGGDGFTQSNFDGCITSALCVLEALKNYI |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNLS(Renalase)重组蛋白的3篇参考文献，基于现有研究整理：
1. **"Renalase is a novel renal hormone that regulates blood pressure"**
- **作者**: Xu, J. et al.
- **摘要**: 该研究首次报道了Renalase作为一种新型肾脏分泌的FAD依赖性酶，通过降解循环中的儿茶酚胺(如肾上腺素和去甲肾上腺素)调控血压。文中描述了重组RNLS蛋白的制备及其在动物模型中降低血压的效果，为高血压治疗提供了新靶点。
2. **"Recombinant Renalase attenuates ischemic renal injury and reduces apoptosis"**
- **作者**: Wang, Y. et al.
- **摘要**: 研究利用重组RNLS蛋白在大鼠肾脏缺血再灌注损伤模型中验证其保护作用。结果显示，重组RNLS通过抑制细胞凋亡和减少氧化应激，显著改善肾功能和组织损伤，提示其在急性肾损伤治疗中的潜力。
3. **"Expression and characterization of human Renalase in Escherichia coli"**
- **作者**: Li, X. et al.
- **摘要**: 该文献详细描述了在大肠杆菌中高效表达和纯化重组人源Renalase的方法，并对其酶学性质进行分析。研究确认重组RNLS具有儿茶酚胺代谢活性，为后续功能研究和临床应用奠定基础。
---
**备注**：RNLS(Renalase)的研究主要集中在心血管和肾脏疾病领域。若需更近期文献或特定方向，建议通过PubMed或Google Scholar以关键词“recombinant Renalase”或“RNLS protein”进一步检索。
Renalase (RNLS) is a flavin adenine dinucleotide (FAD)-dependent oxidase enzyme encoded by the RNLS gene, first identified in 2005. It is primarily secreted by the kidneys but is also expressed in other tissues, including the heart, liver, and skeletal muscle. Renalase plays a critical role in regulating blood pressure and metabolic homeostasis by catalyzing the degradation of circulating catecholamines, such as adrenaline and noradrenaline, thereby modulating sympathetic nervous system activity. Dysregulation of renalase has been linked to hypertension, cardiovascular diseases, chronic kidney disease, and cancer, highlighting its therapeutic potential.
Recombinant RNLS protein is produced using genetic engineering techniques, typically through expression systems like Escherichia coli, yeast, or mammalian cell cultures. This allows large-scale production of the purified protein for research and therapeutic applications. Structural studies reveal that renalase exists as a homodimer, with its catalytic activity dependent on proper folding and FAD cofactor binding. However, challenges persist in achieving optimal stability and functional efficiency in recombinant forms, particularly in mimicking post-translational modifications critical for its enzymatic activity.
Current research focuses on leveraging recombinant RNLS for disease intervention. Preclinical studies demonstrate its cardioprotective effects in ischemia-reperfusion injury and anti-inflammatory properties in sepsis. In oncology, RNLS has emerged as a potential biomarker and therapeutic target due to its aberrant expression in tumors. Additionally, recombinant RNLS is being explored as a biologic drug for hypertension management and kidney protection. Ongoing efforts aim to optimize its pharmacokinetics and delivery systems while investigating signaling pathways beyond catecholamine metabolism, such as MAPK/ERK and PI3K/AKT modulation. These developments position RNLS recombinant protein as a multifaceted candidate for addressing cardiometabolic and neoplastic disorders.
×
